Varied pathways of stage IA lung adenocarcinomas discovered by integrated gene expression analysis

International Journal of Biological Sciences

Volumn 7, Issue 5, 2011, Pages 551-566

  Chen, Chengwen ^a   Fu, Xuping ^a   Zhang, Deqiang ^a   Li, Yuan ^a   Xie, Yi ^a   Li, Yao ^a   Huang, Yan ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Lung adenocarcinoma; Meta analysis; Pathway; Sample size

Indexed keywords

EID: 79955753093     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.7.551     Document Type: Article

References (82)

1. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008; 100: 1672-1694.
2. Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci. 2006; 63: 449-468.
3. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2005; 439: 353-357.
4. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev. 2003; 83: 337-376.
5. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung. Chest. 2004; 126: 347-351.
6. Travis WD, Garg K, Franklin WA, Wistuba II, Sabloff B, et al.Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. Journal of Thoracic Oncology. 2006; 1: S13.
7. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: Iarc. 2004
8. Kratz JR, Jablons DM. Genomic Prognostic Models in Early-Stage Lung Cancer. Clinical Lung Cancer. 2009; 10: 151-157.
9. Rami-Porta R, Crowley JJ, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg. 2009; 15: 4-9.
10. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. New England Journal of Medicine. 2004; 350: 379.
11. Booth CM, Shepherd FA. Adjuvant chemotherapy for resected non-small cell lung cancer. Journal of Thoracic Oncology. 2006; 1: 180.
12. Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, et al. The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer. Annals of Thoracic and Cardiovascular Surgery. 2007; 13: 73.
13. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. The New England journal of medicine. 2004; 350: 1713.
14. Ramaswamy S, Golub TR. DNA microarrays in clinical oncology. Journal of Clinical Oncology. 2002; 20: 1932.
15. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. The New England journal of medicine. 2007; 356: 11.
16. Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest. 2007; 117: 3436-3444.
17. Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. Journal of Clinical Oncology. 2007; 25: 5562.
18. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403: 503-511.
19. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet. 2003; 362: 1439-1444.
20. Jafari P, Azuaje F. An assessment of recently published gene expression data analyses: reporting experimental design and statistical factors. BMC Med Inform Decis Mak. 2006; 6: 27.
21. Warnat P, Eils R, Brors B. Cross-platform analysis of cancer microarray data improves gene expression based classification of phenotypes. BMC Bioinformatics. 2005; 6: 265.
22. Ramasamy A, Mondry A, Holmes CC, Altman DG. Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med. 2008; 5: e184.
23. Brambilla E, Gazdar A. Pathogenesis of lung cancer signaling pathways: roadmap for therapies. European Respiratory Journal. 2009; 33: 1485.
24. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 2002; 62: 4427-4433.
25. Adams MD, Soares MB, Kerlavage AR, Fields C, Venter JC. Rapid cDNA sequencing (expressed sequence tags) from a directionally cloned human infant brain cDNA library. Nat Genet. 1993; 4: 373-380.
26. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society, Series B (Methodological). 1995; 57(1): 289-300.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25: 402-408.
28. Luo Y, Liang F, Zhang ZY. PRL1 Promotes Cell Migration and Invasion by Increasing MMP2 and MMP9 Expression through Src and ERK1/2 Pathways (dagger). Biochemistry. 2009; 48: 1838-1846.
29. Cheng CY, Hsieh HL, Sun CC, Lin CC, Luo SF, et al. IL-1 beta induces urokinase-plasminogen activator expression and cell migration through PKC alpha, JNK1/2, and NF-kappaB in A549 cells. J Cell Physiol. 2009; 219: 183-193.
30. Kedrin D, Wyckoff J, Boimel PJ, Coniglio SJ, Hynes NE, et al. ERBB1 and ERBB2 Have Distinct Functions in Tumor Cell Invasion and Intravasation. Clin Cancer Res. 2009; 15: 3733-3739.
31. Malinowski DP. Minichromosome Maintenance (MCM) Proteins as Tumor Markers: The Detection of MCM Proteins as Markers of Aberrant S-Phase Entry in Cervical Neoplasia. Tumor Markers Research Focus. 2007;: 47.
32. Sowiński J, Mazurek U, Bierzyńska-Macyszyn G. Histone mRNA in situ hybridization in assessing proliferative activity of normal and malignant cells. Folia histochemica et cytobiologica/Polish Academy of Sciences,Polish Histochemical and Cytochemical Society. 2002; 40: 335.
33. Orchel J, Slowinski J, Mazurek U, Wilczok T. H3 mRNA level as a new proliferative marker in astrocytomas. BBA-Molecular Basis of Disease. 2004; 1689: 42-46.
34. Lu JG, Sun YN, Wang C, Jin DJ, Liu M. Role of the αv-integrin subunit in cell proliferation, apoptosis and tumor metastasis of laryngeal and hypopharyngeal squamous cell carcinomas: a clinical and in vitro investigation. European Archives of Oto-Rhino-Laryngology. 2009; 266: 89-96.
35. Marsh D, Dickinson S, Neill GW, Marshall JF, Hart IR, et al. {alpha} v {beta} 6 Integrin Promotes the Invasion of Morphoeic Basal Cell Carcinoma through Stromal Modulation. Cancer research. 2008; 68: 3295.
36. Giancotti FG. Targeting integrin β4 for cancer and anti-angiogenic therapy. Trends in Pharmacological Sciences. 2007; 28: 506-511.
37. Nakano KY, Iyama KI, Mori T, Yoshioka M, Hiraoka T, et al. Loss of alveolar basement membrane type IV collagen 3, 4, and 5 chains in bronchioloalveolar carcinoma of the lung.J Pathol.2001; 194: 420-427.
38. Miyoshi A, Kitajima Y, Sumi K, Sato K, Hagiwara A, et al. Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. British journal of cancer. 2004; 90: 1265.
39. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92: 347-355.
40. Kuo SJ, Chen ST, Yeh KT, Hou MF, Chang YS, et al. Disturbance of circadian gene expression in breast cancer. Virchows Arch. 2009; 454: 467-474.
41. Mostafaie N, Kallay E, Sauerzapf E, Bonner E, Kriwanek S, et al. Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog. 2009; 48: 642-647.
42. Pogue-Geile KL, Lyons-Weiler J, Whitcomb DC. Molecular overlap of fly circadian rhythms and human pancreatic cancer. Cancer Lett. 2006; 243: 55-57.
43. Yeh KT, Yang MY, Liu TC, Chen JC, Chan WL, et al. Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol. 2005; 206: 111-120.
44. Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC, et al. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog. 2008; 47: 925-933.
45. Lasorella A, Uo T, Iavarone A. Id proteins at the cross-road of development and cancer. Oncogene. 2001; 20: 8326-8333.
46. Nguewa PA, Agorreta J, Blanco D, Lozano MD, Gomez-Roman J, et al. Identification of importin IPO8)as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Mol Biol. 2008; 9: 103.
47. Morimoto I, Sasaki Y, Ishida S, Imai K, Tokino T. Identification of the osteopontin gene as a direct target of TP53. Genes Chromosomes Cancer. 2002; 33: 270-278.
48. Toyokuni S, Okamoto K, Yodoi J, Hiai H. Persistent oxidative stress in cancer. FEBS Lett. 1995; 358: 1-3.
49. Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008; 266: 6-11.
50. Moreno-Sanchez R, Rodriguez-Enriquez S, Saavedra E, Marin-Hernandez A, Gallardo-Perez JC. The bioenergetics of cancer: Is glycolysis the main ATP supplier in all tumor cells? Biofactors. 2009; 35: 209-225.
51. Chen X, Sievers E, Hou Y, Park R, Tohme M, et al. Integrin alpha v beta 3-targeted imaging of lung cancer. Neoplasia. 2005; 7: 271-279.
52. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004; 10: 789-799.
53. Carelli S, Zadra G, Vaira V, Falleni M, Bottiglieri L, et al. Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer. 2006; 53: 263-271.
54. Hirano T, Morii H, Nakazawa K, Murakami D, Yamashita A, et al. Enhancement of adipogenesis induction by conditioned media obtained from cancer cells. Cancer Lett. 2008; 268: 286-294.
55. Motrescu ER, Rio MC. Cancer cells, adipocytes and matrix metalloproteinase 11: a vicious tumor progression cycle. Biol Chem. 2008; 389: 1037-1041.
56. Bouloumie A, Sengenes C, Portolan G, Galitzky J, Lafontan M. Adipocyte produces matrix metalloproteinases 2 and 9: involvement in adipose differentiation. Diabetes. 2001; 50: 2080-2086.
57. Gery S, Komatsu N, Kawamata N, Miller CW, Desmond J, et al. Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res. 2007; 13: 1399-1404.
58. Kamalian L, Gosney JR, Forootan SS, Foster CS, Bao ZZ, et al. Increased expression of Id family proteins in small cell lung cancer and its prognostic significance. Clin Cancer Res. 2008; 14: 2318-2325.
59. Rollin J, Blechet C, Regina S, Tenenhaus A, Guyetant S, et al. The intracellular localization of ID2 expression has a predictive value in non small cell lung cancer. PLoS ONE. 2009; 4: e4158.
60. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis. 2009; 30: 377-386.
61. Murata T, Lin MI, Aritake K, Matsumoto S, Narumiya S, et al. Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci U S A. 2008; 105: 20009-20014.
62. Zheng Y, Ritzenthaler JD, Sun X, Roman J, Han S. Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1. Cancer Res. 2009; 69: 896-904.
63. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, et al. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biomarkers Prev. 2007; 16: 416-421.
64. Antoine-Jonville S, Hue O. Cholesterol, statins, and mortality. Lancet. 2008; 371: 1163.
65. Cauley JA, McTiernan A, Rodabough RJ, LaCroix A, Bauer DC, et al. Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst. 2006; 98: 700-707.
66. Kuoppala J, Lamminpaa A, Pukkala E. Statins and cancer: A systematic review and meta-analysis. Eur J Cancer. 2008; 44: 2122-2132.
67. Mori K, Shibanuma M, Nose K. Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res. 2004; 64: 7464-7472.
68. Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kinnula VL. Differential expression of superoxide dismutases in lung cancer. American journal of clinical pathology. 2004; 122: 395-404.
69. Yoo DG, Song YJ, Cho EJ, Lee SK, Park JB, et al. Alteration of APE1/ref-1 expression in non-small cell lung cancer: The implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. Lung cancer. 2008; 60: 277-284.
70. Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature Reviews Drug Discovery. 2009; 8: 579-591.
71. Ray S, Watkins DN, Misso NLA, Thompson PJ. Oxidant stress induces gamma-glutamylcysteine synthetase and glutathione synthesis in human bronchial epithelial NCI-H292 cells. Clinical & Experimental Allergy. 2002; 32: 571-577.
72. Gogvadze V, Zhivotovsky B, Orrenius S. The Warburg effect and mitochondrial stability in cancer cells. Molecular aspects of medicine. 2009; 31: 60-74.
73. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. American Journal of Physiology- Cell Physiology. 2007; 292: C125.
74. Gillies RJ, Gatenby RA. Adaptive landscapes and emergent phenotypes: why do cancers have high glycolysis? Journal of Bioenergetics and Biomembranes. 2007; 39: 251-257.
75. Koukoulis GK, Warren WH, Virtanen I, Gould VE. Immunolocalization of integrins in the normal lung and in pulmonary carcinomas. Human pathology. 1997; 28: 1018-1025.
76. Arenberg D.Bronchioloalveolar Lung Cancer.Chest. 2007; 132: 306S.
77. Saito YD, Jensen AR, Salgia R, Posadas EM. Fyn: a novel molecular target in cancer. Cancer. 2010; 116: 1629-1637.
78. Germain CS, Niknejad N, Ma L, Garbuio K, Hai T, et al. Cisplatin Induces Cytotoxicity through the Mitogen-Activated Protein Kinase Pathways and Activating Transcription Factor 3. Neoplasia. 2010; 12: 527-538.
79. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer research. 2007; 67: 3364.
80. Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer research. 2004; 64: 31.
81. Tuttle SW, Varnes ME, Mitchell JB, Biaglow JE. Sensitivity to chemical oxidants and radiation in CHO cell lines deficient in oxidative pentose cycle activity. International Journal of Radiation Oncology* Biology* Physics. 1992; 22: 671-675.
82. Averillbates DA, Przybytkowski E. The role of glucose in cellular defenses against cytotoxicity of hydrogen peroxide in Chinese hamster ovary cells. Archives of biochemistry and biophysics. 1994; 312: 52-58.